Home › Apricus Biosciences Enrolls First Patients in Phase 2b Clinical Trial ...
 

Keywords :   


Apricus Biosciences Enrolls First Patients in Phase 2b Clinical Trial ...

2015-06-01 20:27:17| Biotech - Topix.net

Apricus Biosciences, Inc. , a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has begun enrolling patients in a Phase 2b clinical trial to evaluate Apricus' novel product candidate, fispemifene, a selective estrogen receptor modulator , for the treatment of men with symptomatic secondary hypogonadism also known as low testosterone. The Phase 2 proof-of-concept clinical trial is a randomized, double-blind, placebo-controlled, parallel arm, multi-center study in approximately 160 hypogonadal men aged 18 to 64 who present with sexual dysfunction related to secondary hypogonadism, or low levels of testosterone.

Tags: trial phase patients clinical

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.05Canada invests over $9.6M to prevent, prepare for African swine fever
20.05Dabbagh Named General Manager of Waldencast Ventures Glaze Brand
20.05Several pork priorities secured in House Farm Bill
20.05BT scraps digital landline switch deadline
20.05Essie Introduces Nail Art Studio
20.05Ilia Beauty Introduces Vegan Lip Sketch Hydrating Crayon
20.05Summer interest rate cut possible, says Bank deputy
20.05Eastern North Pacific Tropical Weather Outlook
More »